Metal Oxide Nanoparticles as Efficient Nanocarriers for Targeted Cancer Therapy: Addressing Chemotherapy-Induced Disabilities
Cancers · 19.12.2024 · 16 (24) · 4234
DOI: 10.3390/cancers16244234 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.12.2024. Verfasst von Mohamed Taha Yassin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Salman center For Disability Research.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Cancer remains a predominant global health concern, necessitating effective treatment options. Conventional cancer therapies, particularly chemotherapy, often face constraints such as low selectivity, insufficient solubility, and multidrug resistance (MDR), which diminish effectiveness and exacerbate negative effects. Metal oxide nanoparticles (MONPs), such as iron oxide, zinc oxide, and copper oxide, offer a promising solution by enhancing targeted drug delivery, reducing systemic toxicity, and mitigating chemotherapy-induced disabilities like neurotoxicity and cardiotoxicity. Nanocarriers conjugated with drugs can improve drug delivery within the body and enhance their circulation in the bloodstream. Recent advancements in MONP synthesis and functionalization have further improved their stability and drug-loading capacity, making them a valuable tool in cancer treatment. MONPs have distinctive physicochemical characteristics, enabling better imaging, drug encapsulation, and targeted medication delivery to cancerous cells. These nanocarriers enhance treatment effectiveness through focused and controlled drug release, reducing off-target effects and addressing drug resistance. This review aims to explore the potential of MONPs as efficient nanocarriers for anticancer drugs, addressing limitations of traditional chemotherapy such as poor specificity, systemic toxicity, and drug resistance. Additionally, the review discusses recent advancements in MONP synthesis and functionalization, which enhance their stability, drug-loading capacity, and compatibility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
- King Salman Center for Disability Research, Riyadh 11614, Saudi Arabia.
- College of Medicine Research Center, King Saud University, Riyadh 11451, Saudi Arabia.
- Botany and Microbiology Department, Faculty of Science, Benha University, Benha 13511, Egypt.
ORCID-Profile: Mohamed Taha Yassin, Fatimah O Al-Otibi, Sarah A Al-Sahli, Mohammad S El-Wetidy
Förderung
- King Salman center For Disability Research
Zitieren
APA
Yassin, M. T., Al-Otibi, F. O., Al-Sahli, S. A., El-Wetidy, M. S., & Mohamed, S. (2024). Metal Oxide Nanoparticles as Efficient Nanocarriers for Targeted Cancer Therapy: Addressing Chemotherapy-Induced Disabilities. Cancers, 16(24), 4234. https://doi.org/10.3390/cancers16244234
Vancouver
Yassin MT, Al-Otibi FO, Al-Sahli SA, El-Wetidy MS, Mohamed S. Metal Oxide Nanoparticles as Efficient Nanocarriers for Targeted Cancer Therapy: Addressing Chemotherapy-Induced Disabilities. Cancers. 2024;16(24):4234. doi:10.3390/cancers16244234
BibTeX
@article{Yassin2024,
author = {Yassin, Mohamed Taha and Al-Otibi, Fatimah O and Al-Sahli, Sarah A and El-Wetidy, Mohammad S and Mohamed, Sara},
title = {Metal Oxide Nanoparticles as Efficient Nanocarriers for Targeted Cancer Therapy: Addressing Chemotherapy-Induced Disabilities},
journal = {Cancers},
year = {2024},
volume = {16},
number = {24},
pages = {4234},
doi = {10.3390/cancers16244234}
}
EUVIMED